Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | PREP | P48147 | 1/20 | 0.33 |
| ▸ | FAP | Q12884 | 1/20 | 0.33 |
| ▸ | HTR6 | P50406 | 1/20 | 0.31 |
| ▸ | XPNPEP1 | Q9NQW7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL666821 | 1.00 | DPP4 (0.33) | DPP4PREPFAPHTR6XPNPEP1 | |
| SCHEMBL4194106 | 1.00 | DPP4 (0.33) | DPP4PREPFAPHTR6XPNPEP1 | |
| SCHEMBL3940874 | 0.73 | — | — | |
| SCHEMBL4991660 | 0.73 | — | — | |
| SCHEMBL10470902 | 0.69 | — | — | |
| SCHEMBL718205 | 0.69 | FUCA1 (0.35) | DPP4PREPFAP | |
| SCHEMBL666257 | 0.69 | FUCA1 (0.35) | DPP4PREPFAP | |
| SCHEMBL8391559 | 0.69 | ADH1B (0.41) | DPP4PREPFAP | |
| SCHEMBL5783979 | 0.69 | ADH1B (0.41) | DPP4PREPFAPXPNPEP1 | |
| SCHEMBL2841819 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060205697-A1 | Novel betulin derivatives, preparation thereof and use thereof | MYREXIS, INC. | 2006-09-14 | — | — | US | claimed |
| US-20170096446-A1 | Extended Triterpene Derivatives | MYREXIS, INC. (US) | 2017-04-06 | — | — | US | disclosed |
| US-9505800-B2 | Extended triterpene derivatives | MYREXIS, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-20120046291-A1 | Extended Triterpene Derivatives | MYREXIS, INC. | 2012-02-23 | — | — | US | disclosed |
| US-20060205697-A1 | Novel betulin derivatives, preparation thereof and use thereof | MYREXIS, INC. | 2006-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205697-A1 | Novel betulin derivatives, preparation thereof and use thereof | BET1, PGGT1B, TMPO | DPP4 1940/4885PREP 1351/4885FAP 3873/4885 |
| US-20170096446-A1 | Extended Triterpene Derivatives | BET1, PGGT1B, TMPO | DPP4 827/4885PREP 2626/4885FAP 4793/4885 |
| US-20120046291-A1 | Extended Triterpene Derivatives | BET1, PGGT1B, TMPO | DPP4 827/4885PREP 2626/4885FAP 4793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.